Drug options for chronic nephritis in reducing proteinuria include renin-angiotensin-aldosterone receptor antagonists (valsartan, benazepril), and sodium-glucose cotransporter protein 2 (SGLT2) inhibitors (dagliflozin). The guidelines continue to recommend renin-angiotensin-aldosterone receptor antagonists such as enalapril and valsartan as first-line agents for the treatment of hypertension and proteinuria at the maximum dose or maximum tolerated dose. SGLT2 inhibitors, as a class of hypoglycemic agents, reduce the risk of both renal and cardiovascular complications and death in diabetic patients, as well as the risk of major adverse renal events and cardiovascular complications and death in nondiabetic causes of chronic kidney disease. SGLT2 inhibitors in the treatment of diabetes mellitus or non-diabetic chronic kidney disease, you can choose dagliflozin, engeletin, cagliflozin, etc., in the lowering of glucose at the same time can reduce urinary protein, therefore, at present, the clinical can also be used in the choice of this class of drugs for chronic nephritis urinary protein patients treatment. It is recommended that patients with chronic nephritis go to regular hospitals in time and follow the doctor’s instructions to standardize the treatment, so as not to delay the condition.